Learn More About New STAAR Study And How Gene Therapy May Help With Your Fabry Disease. See If You Qualify to Join The STAAR Study Today?
- See If You Qualify Today
Find out if you qualify for our
clinical trial.
- Contact Us
Contact us for more information
about our Sangamo study.
- Diagnosed With Fabry?
Exploring The Potential of New
Gene Therapy For Fabry Disease
- Fabry Disease
Learn more about
Sangamo Fabry
- Glossary
Learn More About Our
Extensive Glossary.
- Study Overview
Learn more about the Sangamo
Fabry Clinical Study
- See If You Qualify Today
Search results
Multiple Sclerosis (MS) Multiple sclerosis (MS) is a complex, heterogeneous, chronic disease that requires individualized treatment throughout a patient’s life. The disease involves the central nervous system and disrupts the flow of information within the brain and between the brain and body, signaling unpredictable symptoms. 1.
About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the ...
Feb 23, 2024 · SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the ...
Eisai and Biogen launch Alzheimer's drug Leqembi in China. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.
May 16, 2024 · Biogen Safe Harbor This news release contains forward-looking statements, about the treatment of ALS; the anticipated benefits and potential of Biogen's collaboration arrangements with Ionis; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated with drug development and commercialization.
Biogen. Careers. Students & Graduates. Enrich Your Education. We welcome students and graduates to contribute their passion and creativity to our mission. Our programs include summer internships, six-month co-ops, MBA opportunities, post-doctoral programs, and both PharmD and Ph.D. Fellowships. These opportunities offer invaluable experience in ...
